Chad Beyer

Opinion author

Chad Beyer, PhD, MBA, is a biotech executive with over 25 years of experience advancing CNS therapeutics from discovery through clinical development. Throughout his career, Dr. Beyer has contributed to 34 IND submissions and led more than 10 Phase 1–2 clinical studies across neuropsychiatry and addiction. Dr. Beyer holds a PhD from LSU Medical Center and an MBA from Rutgers Business School and is the founder of Solomon Life Sciences, a drug development consultancy.

AI robotic head gazes at hand holding scales on dark blue background. Ethical decision-making, fairness, and balance in artificial intelligence concept. Low polygonal abstract vector illustration

Opinion

FDA alignment is critical to serving the rare disease community. AI can help

The FDA has introduced models intended to accelerate rare disease drug development, but recent reversals of guidance from the agency speak to a lack of clarity in its implementation. AI can help focus this process.

May 18, 2026

4 min read

Rahul Gupta